Clinical Trial Underway

Our lead therapeutic program focuses on the development of AST-OPC1 for spinal cord injury. AST-OPC1 consists of neural cells known as oligodendrocyte progenitor cells, which are produced from human embryonic stem cells.  OPC1 was previously tested in the world’s first human clinical trial of a pluripotent stem cell derived product. A clinical trial is currently underway testing AST-OPC1 in cervical spinal cord injury. Additional details can be found at

Scientific references for OPC1

Results From Clinical Testing of AST-OPC1 in Thoracic Spinal Cord Injury

In a Phase 1 clinical trial, five patients with neurologically complete, thoracic spinal cord injury were administered two million AST-OPC1 cells at the spinal cord injury site 7-14 days post-injury. The subjects received low levels immunosuppression for the next 60 days.

Delivery of AST-OPC1 was successful in all five subjects with no serious adverse events associated with the administration of the cells, with AST-OPC1 itself, or the immunosuppressive regimen.

In four of the five subjects, serial MRI scans indicated that reduced spinal cord cavitation may have occurred.